Zacks Investment Research on MSN

Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...
Nasdaq

Omeros Awaits FDA Decision On Lead Drug Candidate Narsoplimab Next Month

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...
C&EN

Activation of the ‘complement system’ helps trigger dangerous sickle-cell-disease outcome

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
Frontiers

Factor B as a therapeutic target for the treatment of complement-mediated diseases

The complement system, consisting of three initiating pathways—classical, lectin and alternative, is an important part of innate immunity. Dysregulation of the complement system is implicated in the ...
ahajournals.org

Lectin Complement Pathway and Its Bloody Interactions in Brain Ischemia

Stroke is associated with vascular events that follow the initial insult and involve the activation of several blood-borne cascades including coagulation, contact/kinin, and complement cascade. There ...
Seeking Alpha

Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...